Mice with RyR1 mutation (Y524S) undergo hypermetabolic response to simvastatin

Skeletal Muscle

Volumn 3, Issue 1, 2013, Pages

  Knoblauch, Mark ^a   Dagnino Acosta, Adan ^a   Hamilton, Susan L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium signaling; Myopathy; RyR1; Simvastatin; Statin induced myopathy

Indexed keywords

MUS;

EID: 84883299143     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-3-22     Document Type: Article

References (22)

1. Joy T, Hegele R. Narrative review: statin-related myopathy. Ann Intern Med 2009, 150(12):858-868.
2. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008, 337:1159-1162.
3. Venero C, Thompson P. Managing statin myopathy. Endocrinol Metab Clin North Am 2009, 38(1):121-136.
4. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010, 210(2):337-343.
5. Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud De Mauverger E, Lacampagne A, Mercier J. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012, 259(2):263-268.
6. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008, 8(3):333-338.
7. Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, Raynaud E, Lacampagne A. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun 2005, 338(3):1426-1434.
8. Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005, 329(3):1067-1075.
9. Inoue R, Tanabe M, Kono K, Maruyama K, Ikemoto T, Endo M. Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers. J Pharmacol Sci 2003, 93(3):279-288.
10. Metterlein T, Schuster F, Tadda L, Hager M, Roewer N, Anetseder M. Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals. Cardiovasc Ther 2010, 28(6):356-360.
11. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, Pellissier JF, Cozzone PJ, Amabile N, Bendahan D. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006, 55(4):551-557.
12. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007, 2:21.
13. Chelu M, Goonasekera S, Durham W, Tang W, Lueck J, Riehl J, Pessah I, Zhang P, Bhattacharjee M, Dirksen R, Hamilton SL. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J 2006, 20:329-330.
14. Leung B, Sattar N, Crilly A, Prach M, McCarey D, Payne H, Madhok R, Campbell C, Gracie J, Liew F, McInnes I. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170:1524-1530.
15. Lanner JT, Georgiou DK, Dagnino-Acosta A, Ainbinder A, Cheng Q, Joshi AD, Chen Z, Yarotskyy V, Oakes JM, Lee CS, Monroe TO, Santillan A, Dong K, Goodyear L, Ismailov II, Rodney GG, Dirksen RT, Hamilton SL. AICAR prevents heat-induced sudden death in RyR1 mutant mice independent of AMPK activation. Nat Med 2012, 18(2):244-251.
16. Dagnino-Acosta A, Guerrero-Hernández A. Variable luminal sarcoplasmic reticulum Ca2+buffer capacity in smooth muscle cells. Cell Calcium 2009, 46:188-196.
17. Durham W, Aracena-Parks P, Long C, Rossi A, Goonasekera S, Boncompagni S, Galvan D, Gilman C, Baker M, Shirokova N, Protasi F, Dirksen R, Hamilton S. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 2008, 133:53-65.
18. Herrmann-Frank A, Richter M, Lehmann-Horn F. 4-Chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 1996, 52:149-155.
19. Vattemi G, Gualandi F, Oosterhof A, Marini M, Tonin P, Rimessi P, Neri M, Guglielmi V, Russignan A, Poli C, van Kuppevelt T, Ferlini A, Tomelleri G. Brody disease: insights into biochemical features of SERCA1 and identification of a novel mutation. J Neuropathol Exp Neurol 2010, 69(3):246-252.
20. Voermans N, Laan A, Oosterhof A, van Kuppevelt T, Drost G, Lammens M, Kamsteeg E, Scotton C, Gualandi F, Guglielmi V, van den Heuvel L, Vattemi G, van Engelen B. Brody syndrome: a clinically heterogeneous entity distinct from Brody disease: a review of literature and a cross-sectional clinical study in 17 patients. Neuromuscul Disord 2012, 22:944-954.
21. Belcastro A, Shewchuk L, Raj D. Exercise-induced muscle injury: a calpain hypothesis. Mol Cell Biochem 1998, 179(1-2):135-145.
22. Raastad T, Owe S, Paulsen G, Enns D, Overgaard K, Crameri R, Kiil S, Belcastro A, Bergersen L, Hallén J. Changes in calpain activity, muscle structure, and function after eccentric exercise. Med Sci Sports Exerc 2010, 42(1):86-95.